Omeros Corporation (LON:0KBU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 728.62M +259.7% |
| Revenue (ttm) | 7.49M |
| Net Income | 65.26M |
| EPS | 0.92 |
| Shares Out | n/a |
| PE Ratio | 11.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,781 |
| Open | 13.49 |
| Previous Close | 13.21 |
| Day's Range | 13.19 - 13.80 |
| 52-Week Range | 3.97 - 18.98 |
| Beta | 2.54 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Omeros
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind... [Read more]
News
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Om...
Omeros grants new technology add-on payment status to Yartemlea
Omeros (OMER) Corporation announced that the Centers for Medicare & Medicaid Services, CMS, has granted New Technology Add-On Payment, NTAP, status for Yartemlea under the Fiscal Year 2027 Hospital In...
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLE...
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopat...
Omeros up 11% to $10.89 after AstraZeneca study failure
10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure
Omeros Corporation Investigated by the Portnoy Law Firm
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER) investors that the firm has initiated an investigation ...
Omeros stock crashes on regulatory setback: buy the dip?
Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Med...
Omeros price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Omeros (OMER) to $33 from $40 and keeps a Buy rating on the shares after the “disappointing” negative CHMP…
Omeros announces CHMP adopts negative opinion on MAA for narsoplimab
Omeros (OMER) Corporation announced an update on the review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the company’s marketing authorization application ...
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
Omeros Transcript: AGM 2026
The meeting approved all proposals, including director elections and compensation plans, and highlighted a transformative year with the YARTEMLEA launch, strengthened financials, and pipeline progress. Management addressed shareholder questions on product adoption, competition, and capital strategy.
Omeros Announces Webcast Details for Annual Meeting of Shareholders
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J...
Omeros trading halted, volatility trading pause
09:32 EDT Omeros (OMER) trading halted, volatility trading pause
Omeros Earnings Call Transcript: Q1 2026
YARTEMLEA's U.S. launch drove $9.9M in Q1 net revenue with rapid adoption and strong payer support. Novo Nordisk deal secured $240M upfront, and the company ended Q1 with $135.3M in cash. CMS J-code and NTAP are expected to further boost access and reimbursement.
Omeros Earnings release: Q1 2026
Omeros released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Omeros Quarterly report: Q1 2026
Omeros has published its Q1 2026 quarterly earnings report on May 13, 2026.
Omeros reports Q1 adjusted EPS (24c), consensus (28c)
Reports Q1 revenue $9.89M, consensus $10.05M. “The launch of YARTEMLEA has changed the trajectory of Omeros (OMER), both operationally and financially,” said Gregory A. Demopulos, M.D., Omeros’ Chairm...
Omeros Corporation Reports First Quarter 2026 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include: F...
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros ma...
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
Kyverna Therapeutics (KYTX) announced the appointment of veteran commercial leader Nadia Dac as chief commercial officer, effective May 4. Dac most recently served as chief commercial officer at Omero...
Omeros Proxy statement: Proxy filing
Omeros filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA
Omeros (OMER) Corporation announced that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent Healthcare Common Procedure Coding System J-code for YARTEMLEA. The J-code for YARTE...
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding Sys...
Omeros Earnings Call Transcript: Q4 2025
Q4 2025 saw a transformative asset sale to Novo Nordisk and FDA approval plus rapid U.S. launch of YARTEMLEA, driving a swing to profitability and strengthening the balance sheet. Early YARTEMLEA adoption is robust, with strong payer and formulary support.